MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Pielotax Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Pielotax (Kidney Cytomax A-9) is the kidney-targeted member of Vladimir Khavinson's peptide bioregulator family. It is a 'cytomax', a natural peptide complex (peptide complex A-9) extracted from calf kidney tissue rather than a synthetic single peptide, and is sold as 10 mg oral capsules for renal support. Like other Khavinson peptides, its short kidney-derived peptides are hypothesized to enter cells and modulate tissue-specific gene expression rather than bind a surface receptor (PMID 34834147). Preclinical work reports raised Ki-67, lowered p53, and restored glomerular filtration, creatinine clearance and diuresis after experimental kidney injury (PMID 26515176, 28744634). The real route is oral: 1-2 capsules twice daily with meals (a 20-40 mg daily total) for 15-30 days, repeated after 3-6 months. The subcutaneous reconstitution figures on this page are an educational reference only; there is no validated injectable Pielotax, and it is not approved by the FDA or EMA.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Typical dose: 20-40 mg/day oral (10 mg/cap; 15-30 day course)
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Capsules: store in a dry, dark place at 2-25 °C, protected from moisture. Educational lyophilized-vial model: refrigerate at 2-8 °C and protect from light; once reconstituted, keep at 2-8 °C and use within about 3-4 weeks, avoiding repeated freeze-thaw.
Half-life: Not formally characterized; the constituent short peptides are likely cleared from plasma within minutes, with effects attributed to downstream gene-expression changes that persist days to weeks per course.
Route: Oral capsules taken with meals (plus a sublingual 'Lingual' form) are the real product; this page models a once-daily subcutaneous reconstitution as an educational reference only, a route not validated for Pielotax.
Status: Not FDA or EMA approved; sold in Russia as a kidney-support dietary peptide and elsewhere as a supplement or research material, with evidence limited to Khavinson-group preclinical and small clinical reports.
About Pielotax
Pielotax (Kidney Cytomax A-9) is the kidney-targeted member of Vladimir Khavinson's peptide bioregulator family, a natural peptide complex extracted from calf kidney tissue and sold as oral capsules for renal support [1][4]. The real route should be stated plainly: clinically and commercially Pielotax is an oral capsule taken with food, not an injectable, so the subcutaneous figures below are an educational reconstitution reference modeled on the lyophilized-vial convention used elsewhere on this site, not a validated clinical regimen.\n\nThe documented oral Pielotax dosage is 10 mg of peptide complex A-9 per capsule, taken as 1-2 capsules twice daily with meals (a 20-40 mg daily total) across a 15-30 day course, then repeated after a 3-6 month interval [8]. There are no human injectable Pielotax data, so the per-injection figures here are illustrative only.\n\nEducational guide for reconstitution and short-course dosing.\n\nFrequency: In the educational subcutaneous model, inject once daily during a short course of roughly 15-30 days, mirroring the oral course length. Reconstituting a 20 mg vial with 2 mL of bacteriostatic water yields 10 mg/mL, so a 1-2 mg reference dose corresponds to 10-20 units on a U-100 insulin syringe [1].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2 mL of bacteriostatic water into a sterile syringe.
Inject it slowly down the inner wall of the 20 mg Pielotax vial; do not spray it directly onto the lyophilized powder.
Swirl or roll the vial gently until the powder fully dissolves into a clear solution; never shake, which can shear the peptide and cause foaming.
The result is 10 mg/mL, so 1 mg is 10 units (0.1 mL) and 2 mg is 20 units (0.2 mL) on a U-100 insulin syringe; swab the stopper and draw your reference dose.
Inject subcutaneously once daily during the course, store the vial refrigerated at 2-8 °C between uses, and discard after the ~3-4 week stability window. Remember the clinical product is an oral capsule, so this injectable math is an educational reference only.
Interactive Pielotax Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Conservative course (educational SC reference) | 1000 mcg (1 mg) | 10 units (0.10 mL) |
| Standard course (educational SC reference) | 2000 mcg (2 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Pielotax, 20 mg each):
- checkOne 30-day course at the educational 2 mg/day reference uses 60 mg, about 3 vials (a 1 mg/day course uses about half that).
- check8-week window (typically one 30-day course): about 3 vials.
- check12-week window (usually still one course, as courses are repeated only every 3-6 months): about 3 vials.
- check16-week window (room for up to two spaced courses): about 3-6 vials.
Insulin Syringes (U-100):
- checkOne 0.3 mL (30-unit) syringe per daily injection, about 30 per 30-day course.
- check8-week window: roughly 30 syringes.
- check12-week window: roughly 30 syringes.
- check16-week window: roughly 30-60 syringes for one to two courses.
Bacteriostatic Water (30 mL bottles): Use 2 mL per vial for reconstitution.
- checkEach reconstituted 20 mg vial consumes 2 mL of bacteriostatic water, so a 3-vial course uses about 6 mL.
- checkA single 30 mL bottle comfortably covers several courses across an 8-16 week window.
- checkDiscard any vial not used within its ~3-4 week stability window rather than over-diluting to extend it.
Alcohol Swabs: clean the vial stopper and injection site before each use.
- checkUse 2 swabs per injection (vial top plus skin), about 60 per 30-day course.
- check8-week and 12-week windows: roughly 60 swabs each; 16-week window with two courses: up to about 120.
- checkA single 100-200 count box comfortably covers a full year of seasonal courses.
Mechanism of Action (MOA)
Pielotax belongs to the "cytomax" branch of Vladimir Khavinson's peptide bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike the synthetic "cytogen" tetrapeptides (such as the cardiac Ala-Glu-Asp-Arg or pineal Glu-Asp-Arg sequences), a cytomax like Pielotax is a natural peptide complex, labeled peptide complex A-9, isolated by a patented extraction from the kidney tissue of young calves and yielding a mixture of short kidney-derived peptides and amino acids (glutamic acid, aspartic acid and alanine are listed among the principal residues) [1][4]. The governing hypothesis for the whole class is that these small, charged peptides are taken up by cells, enter the nucleus, and bind specific regulatory regions of DNA, modulating transcription of tissue-appropriate genes rather than acting on a cell-surface receptor [1][7].\n\nIn kidney-specific preclinical work, a calf-kidney polypeptide complex stimulated cell-renewal processes in organotypic kidney cultures from both young and old rats, raising the proliferation marker Ki-67 and lowering the pro-apoptotic protein p53; the short peptides AED and EDL reproduced the effect to a lesser degree [4]. In rat models of cisplatin-induced acute renal failure and of gentamicin- and ischemia/reperfusion-induced injury, kidney peptide preparations and the EDL peptide normalized diuresis, urinary creatinine and its excretion, glomerular filtration rate and sodium handling, while limiting oxidative damage and supporting nephron energy metabolism [2][3]. These are the proposed downstream effects: restored filtration, slowed nephron senescence, and rebalanced proliferation versus apoptosis.\n\nPharmacokinetics have not been formally characterized for Pielotax. As a mixture of short peptides it is expected to be hydrolyzed rapidly by gastrointestinal, plasma and tissue peptidases, giving a free-peptide plasma half-life on the order of minutes; oral bioavailability of intact peptides is inherently low, which is why the product is given as repeated daily capsules over a multi-week course, and why any lasting effect is attributed to downstream gene-expression changes that outlast the peptides themselves rather than to sustained drug levels [1][5].\n\nRoute matters here. Pielotax is a real oral capsule (10 mg of complex A-9 each), taken 1-2 capsules twice daily with meals for 15-30 days and repeated after 3-6 months; a sublingual "Lingual Pielotax" also exists [8]. There is no validated injectable Pielotax and no human subcutaneous data. The once-daily subcutaneous reconstitution on this page is purely an educational modeling convention: reconstituting a 20 mg vial in 2 mL of bacteriostatic water gives 10 mg/mL, so a 1-2 mg reference dose is 10-20 units on a U-100 syringe. Pielotax is not approved by the FDA or EMA; outside Russia it is sold as a dietary supplement or as research material, and the dosing here is reference information only, not medical advice [5][7].
Clinical Trial Efficacy Highlights
- starIn organotypic kidney tissue cultures from young and old rats, a calf-kidney polypeptide complex stimulated cell renewal, raising expression of the proliferation marker Ki-67 and reducing the pro-apoptotic protein p53; the short peptides AED and EDL produced similar but weaker effects, supporting the proposal that the complex shifts aging kidney tissue toward renewal (Bull Exp Biol Med, 2015) [4].
- starIn rats with cisplatin-induced acute renal failure, a kidney polypeptide complex together with the peptides EDL and AEDG normalized diuresis, urinary creatinine concentration and excretion, glomerular filtration rate and sodium resorption, indicating restoration of functional renal markers after toxic injury (Zamorskii et al., 2015) [2].
- starThe EDL peptide produced a nephroprotective effect in rat models of gentamicin-induced nephropathy and ischemia/reperfusion injury, preventing oliguria and azotemia, lowering proteinuria, preserving antioxidant enzyme activity and normalizing nephron energy supply (Zamorskii et al., 2017) [3].
- starA 2021 systematic review in Molecules summarizing the Khavinson short-peptide program describes how 2-7 residue peptides regulate tissue-specific gene expression and protein synthesis; it provides the mechanistic rationale invoked for kidney bioregulators but reports no human efficacy data specific to Pielotax [1].
- starAnisimov and Khavinson's long-term review reported that repeated courses of Khavinson peptide bioregulators increased mean lifespan by roughly 20-40% and reduced age-related pathology in animal models, the broad geroprotective signal that frames the bioregulator class, though it is not a kidney-specific clinical result (Biogerontology, 2010) [5].
- starA small manufacturer-affiliated clinical report from the St. Petersburg Institute of Bioregulation and Gerontology (42 patients with gouty nephropathy, 2011) described improved non-protein nitrogen, urea and uric-acid values and clinical improvement in about 78% of cases with no reported side effects after a 30-day oral course; this is the principal Pielotax-specific human data and is not a peer-reviewed randomized trial [8].
- starAn independent 2019 review in Clinical Epigenetics catalogued Khavinson di- to tetrapeptides as endogenous epigenetic modulators capable of acting as DNA-methylation inhibitors, situating the proposed Pielotax mechanism within an externally authored peptide-epigenetics literature [7].
- starKhavinson's overarching 'Peptides and Ageing' review lays out the tissue-specific geroprotector framework under which the kidney cytomax was designed, but presents the kidney peptides as preclinical bioregulators rather than a clinically validated renal therapy, and nearly all supporting data originate from a single research lineage [6].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo large controlled human safety data exist for Pielotax; the profile is largely uncharacterized, and the points below are extrapolated from small manufacturer-affiliated reports and the Khavinson bioregulator class generally.
- warningThe manufacturer lists contraindications of individual intolerance of the components, pregnancy and lactation; Pielotax has not been evaluated in children or in advanced or dialysis-dependent kidney failure.
- warningBecause Pielotax is a peptide complex extracted from animal (bovine and porcine) tissue, there is a theoretical risk of allergy or hypersensitivity to animal-derived material; discontinue and seek care for rash, hives, swelling or difficulty breathing.
- warningSelf-treating kidney disease with an unapproved peptide instead of evidence-based care is itself a significant risk; people with nephropathy, gout or renal insufficiency should be managed by a nephrologist.
- warningIn the educational subcutaneous model, injection can cause local reactions such as redness, itching, swelling, bruising or transient pain at the injection site; this route has never been validated for Pielotax.
- warningResearch-grade or supplement-grade peptide material is not manufactured to pharmaceutical standards, so contamination, endotoxin, incorrect content or impurity are realistic risks, and sterility and purity cannot be assumed.
- warningThere are no formal drug-interaction studies; people taking medications for gout, hypertension, diabetes or kidney disease should not assume Pielotax is inert or compatible.
- warningRegulatory status: Pielotax is not approved by the FDA, EMA or other major regulators as a drug; it is sold in Russia as a dietary peptide and elsewhere as a supplement or research material, and nothing here should be read as a claim that it is safe or effective for any condition.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Pielotax dosage?expand_more
The documented real-world Pielotax dosage is oral. Each capsule contains 10 mg of kidney peptide complex A-9, and the manufacturer protocol is 1-2 capsules twice daily with meals (a 20-40 mg daily total), taken for a 15-30 day course and repeated after a 3-6 month interval. A 2011 clinical report in gouty nephropathy used 1-2 capsules three times daily for 30 days. There is no validated injectable dose; the 1-2 mg per day subcutaneous figures elsewhere on this page are an educational reconstitution reference only, not a therapeutic recommendation.
Is Pielotax FDA approved?expand_more
No. Pielotax is not approved by the FDA, the EMA, or other major regulators as a drug. It originates from the Khavinson bioregulator program in Russia, where it is sold as a kidney-support dietary peptide; elsewhere it is marketed as a supplement or as research material. No large randomized controlled trials support it, and nothing here should be read as a claim that it treats or prevents kidney disease.
How is Pielotax taken, and how would you reconstitute it for injection?expand_more
Pielotax is a real oral capsule, swallowed with meals; a sublingual form also exists. It is not an injectable product. The reconstitution shown here is an educational modeling exercise only: if a 20 mg lyophilized vial were used, you would draw 2 mL of bacteriostatic water, run it down the vial wall, and swirl (never shake) until clear, giving 10 mg/mL so that 1 mg is 10 units and 2 mg is 20 units on a U-100 syringe. This Pielotax reconstitution math is reference information, not a validated route of administration.
What is Pielotax's half-life?expand_more
Pielotax's half-life has not been formally characterized in published pharmacokinetic studies. As a complex of short kidney-derived peptides, the intact molecules are expected to be broken down within minutes by gastrointestinal, plasma and tissue peptidases. The Khavinson framework attributes any longer-lasting effect to downstream changes in gene expression that outlast the peptides themselves, which is part of why the product is dosed in repeated daily capsules over a multi-week course rather than relying on sustained circulating levels.
Can Pielotax be stacked with other Khavinson bioregulators?expand_more
In the bioregulator literature, tissue-specific cytomaxes are frequently described as being combined (for example a kidney peptide alongside vascular, liver, or thymus peptides), and Pielotax is commonly marketed within such longevity stacks. However, there are no controlled data on the safety, interactions or added benefit of any such combination, and stacking unapproved peptides multiplies the unknown risks. This is general information, not medical advice; anyone considering these compounds, especially with existing kidney disease, should consult a qualified clinician.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Pielotax, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure. Bull Exp Biol Med. 2015;159(6):736-739. View Scientific Paper →
Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis. Bull Exp Biol Med. 2017;163:389-393. View Scientific Paper →
Khavinson VKh, et al. Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. Bull Exp Biol Med. 2015;159(1):124-127. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Janssens Y, Wynendaele E, Vanden Berghe W, De Spiegeleer B. Peptides as epigenetic modulators: therapeutic implications. Clin Epigenetics. 2019;11(1):101. View Scientific Paper →
Clinical study of the biologically active peptide bioregulator Pielotax (gouty nephropathy, 42 patients, St. Petersburg Institute of Bioregulation and Gerontology, 2011). Manufacturer-affiliated clinical report (not peer-reviewed). View Scientific Paper →